Cargando…

HMGB1 in Radiotherapy: A Two Headed Signal Regulating Tumor Radiosensitivity and Immunity

Radiotherapy (RT) is a mainstay of cancer treatment. Recent studies have shown that RT not only directly induces cell death but also has late and sustained immune effects. High mobility group box 1 (HMGB1) is a nuclear protein released during RT, with location-dependent functions. It is essential fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Liao, Yin, Liu, Shuya, Fu, Shaozhi, Wu, Jingbo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7369309/
https://www.ncbi.nlm.nih.gov/pubmed/32764978
http://dx.doi.org/10.2147/OTT.S253772
_version_ 1783560754402689024
author Liao, Yin
Liu, Shuya
Fu, Shaozhi
Wu, Jingbo
author_facet Liao, Yin
Liu, Shuya
Fu, Shaozhi
Wu, Jingbo
author_sort Liao, Yin
collection PubMed
description Radiotherapy (RT) is a mainstay of cancer treatment. Recent studies have shown that RT not only directly induces cell death but also has late and sustained immune effects. High mobility group box 1 (HMGB1) is a nuclear protein released during RT, with location-dependent functions. It is essential for normal cellular function but also regulates the proliferation and migration of tumor cells by binding to high-affinity receptors. In this review, we summarize recent evidence on the functions of HMGB1 in RT according to the position, intracellular HMGB1 and extracellular HMGB1. Intracellular HMGB1 induces radiation tolerance in tumor cells by promoting DNA damage repair and autophagy. Extracellular HMGB1 plays a more intricate role in radiation-related immune responses, wherein it not only stimulates the anti-tumor immune response by facilitating the recognition of dying tumor cells but is also involved in maintaining immunosuppression. Factors that potentially affect the role of HMGB1 in RT-induced cytotoxicity have also been discussed in the context of possible therapeutic applications, which helps to develop effective and targeted radio-sensitization therapies.
format Online
Article
Text
id pubmed-7369309
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-73693092020-08-05 HMGB1 in Radiotherapy: A Two Headed Signal Regulating Tumor Radiosensitivity and Immunity Liao, Yin Liu, Shuya Fu, Shaozhi Wu, Jingbo Onco Targets Ther Review Radiotherapy (RT) is a mainstay of cancer treatment. Recent studies have shown that RT not only directly induces cell death but also has late and sustained immune effects. High mobility group box 1 (HMGB1) is a nuclear protein released during RT, with location-dependent functions. It is essential for normal cellular function but also regulates the proliferation and migration of tumor cells by binding to high-affinity receptors. In this review, we summarize recent evidence on the functions of HMGB1 in RT according to the position, intracellular HMGB1 and extracellular HMGB1. Intracellular HMGB1 induces radiation tolerance in tumor cells by promoting DNA damage repair and autophagy. Extracellular HMGB1 plays a more intricate role in radiation-related immune responses, wherein it not only stimulates the anti-tumor immune response by facilitating the recognition of dying tumor cells but is also involved in maintaining immunosuppression. Factors that potentially affect the role of HMGB1 in RT-induced cytotoxicity have also been discussed in the context of possible therapeutic applications, which helps to develop effective and targeted radio-sensitization therapies. Dove 2020-07-14 /pmc/articles/PMC7369309/ /pubmed/32764978 http://dx.doi.org/10.2147/OTT.S253772 Text en © 2020 Liao et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Review
Liao, Yin
Liu, Shuya
Fu, Shaozhi
Wu, Jingbo
HMGB1 in Radiotherapy: A Two Headed Signal Regulating Tumor Radiosensitivity and Immunity
title HMGB1 in Radiotherapy: A Two Headed Signal Regulating Tumor Radiosensitivity and Immunity
title_full HMGB1 in Radiotherapy: A Two Headed Signal Regulating Tumor Radiosensitivity and Immunity
title_fullStr HMGB1 in Radiotherapy: A Two Headed Signal Regulating Tumor Radiosensitivity and Immunity
title_full_unstemmed HMGB1 in Radiotherapy: A Two Headed Signal Regulating Tumor Radiosensitivity and Immunity
title_short HMGB1 in Radiotherapy: A Two Headed Signal Regulating Tumor Radiosensitivity and Immunity
title_sort hmgb1 in radiotherapy: a two headed signal regulating tumor radiosensitivity and immunity
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7369309/
https://www.ncbi.nlm.nih.gov/pubmed/32764978
http://dx.doi.org/10.2147/OTT.S253772
work_keys_str_mv AT liaoyin hmgb1inradiotherapyatwoheadedsignalregulatingtumorradiosensitivityandimmunity
AT liushuya hmgb1inradiotherapyatwoheadedsignalregulatingtumorradiosensitivityandimmunity
AT fushaozhi hmgb1inradiotherapyatwoheadedsignalregulatingtumorradiosensitivityandimmunity
AT wujingbo hmgb1inradiotherapyatwoheadedsignalregulatingtumorradiosensitivityandimmunity